BIOCYTOGEN-B (02315) announced that to enhance the efficiency of its own capital utilization, the company intends to reasonably use a portion of its idle own funds for cash management, provided that it does not affect normal production and operations and ensures the safety of the funds. This initiative can improve the efficiency of capital use, increase returns on the company's cash assets, and secure more investment returns for the company and its shareholders. The company plans to use up to RMB 500 million (inclusive) in temporarily idle own funds for cash management. Within the aforementioned limit, the funds can be recycled and rolled over for use. The company intends to use the temporarily idle own funds to purchase wealth management products issued by banks and other financial institutions that are characterized by high security, good liquidity, and low risk for entrusted financial management.